Mutations in the genes encoding cytosolic aminoacyl-tRNA synthetases are responsible for early-onset multisystemic diseases including to varying degrees interstitial lung disease, liver damage, neurological and digestive disorders, and systemic inflammation. These are rare and severe diseases whose pathophysiology is poorly understood. The investigative team hypothesizes that mutations within these genes are responsible for a decrease in protein translation and lead to a cellular stress response similar to that induced by amino acid deprivation. The investigative team also hypothesizes that these alterations could be corrected by high-dose supplementation in the culture medium of the corresponding amino acid. The main objective of the study is to precisely determine the consequences of cytosolic aminoacyl-tRNA synthetase mutations at the cell level on protein translation.
Mutations in the genes encoding cytosolic aminoacyl-tRNA synthetases are responsible for early-onset multisystemic diseases including to varying degrees interstitial lung disease, liver damage, neurological and digestive disorders, and systemic inflammation. These are rare and severe diseases whose pathophysiology is poorly understood. The investigative team hypothesizes that mutations within these genes are responsible for a decrease in protein translation and lead to a cellular stress response similar to that induced by amino acid deprivation. The investigative team also hypothesizes that these alterations could be corrected by high-dose supplementation in the culture medium of the corresponding amino acid. The main objective of the study is to precisely determine the consequences of cytosolic aminoacyl-tRNA synthetase mutations at the cell level on protein translation. The parameters below will be studied in vitro in cell culture from skin biopsies of patients and control cells: * Determination of total protein content * The incorporation of d-methionine, leucine, tyrosine or phenylalanine into proteins * The study of polysomes profiling * The study of the assembly of the ribosomal 43S pre-initiation complex * The phosphorylation of eIF2α and 4EBP and the expression of ATF4 * Ribosome profiling * Transfer RNA (tRNA) sequencing * The production of reactive oxygen species (ROS) The results of these studies will be compared: * Between patient cells and control cells * Between genetically corrected patient cells, by stable transfection of the wild-type cDNA of the concerned genes and uncorrected cells * Between patient cells cultured in medium enriched with the corresponding amino acid.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
A skin biopsy performed on the forearm or thigh depending on the patient's age and wishes, with a biopsy punch with a diameter of 3 to 4 mm depending on the child's age (3 for children under 3 years, 4 beyond). Culture of fibroblasts and immortalization.
Hôpital Necker-Enfants Malades
Paris, France
Determination of total protein content
Determination of total protein content by Bicinchoninic acid assay.
Time frame: Day 0
Incorporation of d-methionine and d-phenylalanine into proteins
Incorporation of methionine and phenylalanine by labelled amino-acid fluorescent assays using ready-to-use kits.
Time frame: Day 0
Study of polysomes profiling
Study of polysome profils by differential sedimentation on sucrose gradients.
Time frame: Day 0
Study of the assembly of the ribosomal 43S pre-initiation complex
Study of the assembly of the ribosomal 43S pre-initiation complex by co-immunoprecipitation experiments.
Time frame: Day 0
Phosphorylation of eIF2α and 4EBP and the expression of ATF4
Phosphorylation of eIF2α and 4EBP and the expression of ATF4 by western blot.
Time frame: Day 0
Ribosome profiling
Ribosome profiling by high throughput sequencing.
Time frame: Day 0
Transfer RNA (tRNA) sequencing
Transfer RNA (tRNA) sequencing by high throughput sequencing.
Time frame: Day 0
Production of reactive oxygen species (ROS)
Production of reactive oxygen species (ROS) by fluorescent measurement after cells' incubation with 2',7'- dichlorodihydrofluorescein diacetate (H2DCFDA).
Time frame: Day 0
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.